Article

Treatment with local hemostatic agents and primary closure after tooth extraction in warfarin treated patients.

Department of Oral Surgery and Oral Medicine Faculty of Odontology, Malmö University, Malmo, Sweden.
Swedish dental journal (Impact Factor: 1.08). 01/2013; 37(2):71-7.
Source: PubMed

ABSTRACT The aim of this retrospective study was to assess the frequency of postoperative bleeding in patients on warfarin after tooth removal followed by a complete soft tissue closure of the surgical site. A total of 124 consecutive patients, 69 males and 55 females with a mean age of 71 years (range 28-95 years) were included in this study. Inclusion criteria were patients on warfarin with an INR <or=3.5 who were referred for tooth removal (single or multiple) during 2004-2009. After tooth extraction all sockets were packed with an absorbable haemostatic gelatin sponge or a collagen fleece and subsequently the sockets was primary closed with sutures. 5/124 (4%) patients returned with postoperative bleedings. All patients with a postoperative bleeding had received a surgical extraction in the posterior part of the maxilla. Consequently no patient had a postoperative bleeding in the mandible. None of the 124 patients returned to the clinic with a dry socket or postoperative pain. 3/124 (2%) patients returned with postoperative infection that required antibiotic treatment. All patients who bled were managed conservatively and none was admitted to hospital.
According to the protocol of this study (local hemostatic, primary closure, sutures and tranexamic acid) the risk of postoperative bleeding after tooth removal in patients on continued warfarin medication is low.

Full-text

Available from: Jonas P Becktor, Apr 21, 2014
1 Follower
 · 
152 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In a literature review, the incidence and morbidity of bleeding complications after dental surgery in anticoagulated patients was compared with embolic complications when interrupting anticoagulation. Over 99% of anticoagulated patients had no postoperative bleeding requiring more than local hemostatic measures. Of more than 5,431 patients undergoing more than 11,381 surgical procedures, many at higher than present therapeutic INR levels, only 31 (∼0.6% of patients) required more than local hemostasis to control hemorrhage; none died from hemorrhage. Among at least 2,673 patients whose warfarin was reduced or withdrawn for at least 2,775 visits for dental procedures, there were 22 embolic complications (0.8% of cessations), including 6 fatal events (0.2% of cessations). The embolic morbidity risk in patients whose anticoagulation is interrupted for dental surgery exceeds that of significant bleeding complications in patients whose anticoagulation is continued, even when surgery is extensive. Warfarin anticoagulation should not be interrupted for most dental surgery.
    Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 11/2014; 119(2). DOI:10.1016/j.oooo.2014.10.011 · 1.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In patients on antiplatelet medications undergoing dental surgery, physicians and dentists must weigh bleeding risks in continuing antiplatelet medications versus thrombotic risks in interrupting. Bleeding complications requiring more than local measures for hemostasis are exceedingly rare after dental surgery in patients on antiplatelet medications. Conversely, the risk for thrombotic complications after interruption of antiplatelet therapy for dental procedures, while small, is apparently significant. When a clinician is faced with a decision to continue or interrupt antiplatelet therapy for a dental surgical patient, the decision comes down to "bleed or die." That is, there is a remote chance that continuing antiplatelet therapy will result in a (nonfatal) bleeding problem needing more than local measures for hemostasis versus a small but significant chance that interrupting antiplatelet therapy will result in a (possibly fatal) thromboembolic complication. The decision is simple - it is time to stop interrupting antiplatelet therapy for dental surgery.
    The American journal of medicine 12/2013; 127(4). DOI:10.1016/j.amjmed.2013.11.013 · 5.30 Impact Factor